Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL959014 | 0.98 | MPO (0.35) | MPOSMN1; SMN2TAAR1AXLPRKCI | |
| SCHEMBL27979579 | 0.83 | MPO (0.35) | MPOSMN1; SMN2TAAR1AXLPRKCI | |
| SCHEMBL23847865 | 0.80 | PRKCI (0.31) | SMN1; SMN2PRKCILMNAALDH1A1 | |
| SCHEMBL25184014 | 0.79 | MPO (0.37) | MPOSMN1; SMN2TAAR1AXLPRKCI | |
| SCHEMBL26618679 | 0.78 | TDP1 (0.34) | SMN1; SMN2TAAR1LMNAALDH1A1 | |
| SCHEMBL31667708 | 0.78 | NOS2 (0.42) | SMN1; SMN2TAAR1LMNAALDH1A1 | |
| SCHEMBL28065177 | 0.78 | NOS2 (0.42) | SMN1; SMN2TAAR1LMNAALDH1A1 | |
| SCHEMBL31280885 | 0.78 | ALDH1A1 (0.30) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL29825595 | 0.78 | TDP1 (0.34) | SMN1; SMN2TAAR1LMNAALDH1A1 | |
| SCHEMBL26695671 | 0.78 | ALDH1A1 (0.30) | SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431362-A | Substituted heteroaryl carboxylic acid compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-02-14 | — | — | CN | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| CN-104039791-B | [1, 2, 3] triazolo [4, 5-D ] pyrimidine derivatives as cannabinoid receptor 2 agonists | 霍夫曼-拉罗奇有限公司 | 2016-11-09 | — | — | CN | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | MPO 1937/4885SMN1; SMN2 741/4885TAAR1 3086/4885 |
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | MPO 4809/4885SMN1; SMN2 3689/4885TAAR1 4175/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | MPO 2902/4885SMN1; SMN2 1545/4885TAAR1 117/4885 |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | MPO 4810/4885SMN1; SMN2 3357/4885TAAR1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.